What is the current Price Target for the Moonlake Immunotherapeutics stock?

The average Moonlake Immunotherapeutics target price is $30.60. This is 168.89% higher than the current stock price. The highest price target is 545.87%, the lowest is -46.75%. 16 Analysts have issued a price target Moonlake Immunotherapeutics 2027 .

How high will the Moonlake Immunotherapeutics stock rise?

No reliable answer can be given as to how high the Moonlake Immunotherapeutics stock will rise. The performance of stocks, including the Moonlake Immunotherapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Moonlake Immunotherapeutics stock today?

The performance of Moonlake Immunotherapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Moonlake Immunotherapeutics stock fall?

The decline in Moonlake Immunotherapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Moonlake Immunotherapeutics Forecast, price target & analysts

$11.38

0.26%

Nasdaq, Oct 05, 04:00 pm EDT. Closed.

ISIN

KY61559X1045

Symbol

MLTX

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership News Strategies

Moonlake Immunotherapeutics Target price 2026 - Analyst rating & recommendation

Moonlake Immunotherapeutics Classifications & Recommendation

Buy

77%

Hold

14%

Sell

Moonlake Immunotherapeutics Price Target

Target Price	$30.60
Price	$11.38
Potential	168.89% register free of charge
Number of Estimates	16

	16 Analysts have issued a price target Moonlake Immunotherapeutics 2027 . The average Moonlake Immunotherapeutics target price is $30.60. This is 168.89% register free of charge higher than the current stock price. The highest price target is $73.50 545.87% register free of charge , the lowest is $6.06 46.75% register free of charge .
	A rating was issued by 22 analysts: 17 Analysts recommend Moonlake Immunotherapeutics to buy, 3 to hold and 2 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Moonlake Immunotherapeutics stock has an average upside potential 2027 of 168.89% register free of charge . Most analysts recommend the Moonlake Immunotherapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-3.53	-3.43
	86.77%	2.83%
P/E		negative

16 Analysts have issued a Moonlake Immunotherapeutics forecast for earnings per share. The average Moonlake Immunotherapeutics EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-3.53	86.77%
2026	$-3.43 2.83% unlock
2027	$-3.48 1.46% unlock
2028	$-2.71 22.13% unlock
2029	$-1.70 37.27% unlock
2030	$0.34 120.00% unlock
2031	$2.07 508.82% unlock
2032	$3.73 80.19% unlock
2033	$4.54 21.72% unlock

Current	-3.21	85.57%
2026	-3.33 3.90% unlock
2027	-3.28 1.50% unlock
2028	-4.21 28.35% unlock
2029	-6.70 59.14% unlock
2030	33.39 598.36% unlock
2031	5.52 83.47% unlock
2032	3.06 44.57% unlock
2033	2.51 17.97% unlock

Moonlake Immunotherapeutics...

Current Moonlake Immunotherapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Aug 13 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jul 20 2026
Leerink Partners	Locked ➜ Locked	Locked	Jul 01 2026
BTIG	Locked ➜ Locked	Locked	Jun 09 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jun 08 2026
Needham	Locked ➜ Locked	Locked	May 12 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	May 11 2026

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Aug 13 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Jul 20 2026
Locked Leerink Partners: Locked ➜ Locked	Jul 01 2026
Locked BTIG: Locked ➜ Locked	Jun 09 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Jun 08 2026
Locked Needham: Locked ➜ Locked	May 12 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	May 11 2026

Discover more stocks with a high price target

NIO ADR 84.17%

Alibaba Group Holding Ltd 80.17%

Rheinmetall 66.50%

Tencent Holdings Ltd. 60.60%

Adyen 56.10%

BYD 49.89%

Uber Technologies 48.27%

TUI 46.72%

Infineon 45.44%

Siemens Energy 43.75%

Adidas 43.36%

Netflix 42.80%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now